SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    National Comprehensive Cancer Network. NCCN: Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. Version 2. 2011. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed December 13, 2010.
  • 2
    Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27: 6041-6051.
  • 3
    Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362: 2251-2259.
  • 4
    Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010; 362: 2260-2270.
  • 5
    O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994-1004.
  • 6
    Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood. 2009; 114: 462. Abstract 1126.
  • 7
    Jabbour E, Cortes JE, Kantarjian HM. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer. 2008; 112: 2112-2118.
  • 8
    Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006; 108: 1809-1820.
  • 9
    Baccarani M, Giles F, Ottmann O, et al. Long term outcome (progression-free survival) in patients receiving nilotinib for imatinib failure who meet suboptimal response criteria according to European LeukemiaNet 2009 CML recommendations [abstract]. Haematologica. 2010; 95: 53. Abstract 0132.
  • 10
    Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS). Blood. 2010; 116: 3758-3765.
  • 11
    Kantarjian HM, Shan J, Jones D, et al. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol. 2009; 27: 3659-3663.
  • 12
    Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res. 2007; 13: 6136-6143.
  • 13
    Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11: 1029-1035.
  • 14
    Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009; 23: 1054-1061.
  • 15
    Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007; 110: 3540-3546.
  • 16
    Cortes JE, Khoury HJ, Corm S, et al. Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (pts) with the T315I mutation: data from an ongoing phase II/III trial [abstract]. J Clin Oncol. 2009; 27: 358s. Abstract 7008.
  • 17
    Cortes J, Talpaz M, Bixby D, et al. A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings [abstract]. Blood. 2010; 116: 96-97. Abstract 0210.
  • 18
    Gambacorti-Passerini C, Kim DW, Kantarjian HM, et al. An ongoing phase 3 study of bosutinib (SKI-606) versus imatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia [abstract]. Blood. 2010; 116: 95-96. Abstract 0208.
  • 19
    le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008; 111: 1834-1839.
  • 20
    Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007; 109: 2303-2309.
  • 21
    Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007; 109: 4143-4150.
  • 22
    Kantarjian HM, Giles FJ, Bhalla KN, et al. Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes [abstract]. Blood. 2009; 114: 464. Abstract 1129.
  • 23
    Hochhaus AH, Giles F, Apperley J, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study [abstract]. Haematologica. 2009; 94( suppl 2): 256. Abstract 631.
  • 24
    Giles FJ, Larson RA, Kantarjian HM, et al. Nilotinib in chronic myelogenous leukaemia in blast crisis (CML-BC) patients with imatinib-resistance or -intolerance: updated phase 2 results. Hematologica. 2008; 93: 46.
  • 25
    Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010; 95: 232-240.
  • 26
    Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol. 2009; 27: 3472-3479.
  • 27
    Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia. 2008; 22: 2176-2183.
  • 28
    Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of ph(+) chronic myeloid leukemia. Blood. 2009; 114: 4933-4938.
  • 29
    Cortes JE, Jones D, O'Brien S, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010; 28: 392-397.
  • 30
    Hochhaus A, Lobo C, Pasquini R, et al. Continued superiority of nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond 1 year [abstract]. Haematologica. 2010; 95: 459. Abstract 1113.
  • 31
    Larson RA, le Coutre PD, Reiffers J, et al. Comparison of nilotinib and imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond 1 year [abstract]. J Clin Oncol. 2010; 28: 487s. Abstract 6501.
  • 32
    Shah N, Kantarjian H, Hochhaus A, et al. Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up [abstract]. Blood. 2010; 116: 94. Abstract 206.
  • 33
    Hughes TP, Hochhaus A, Saglio G, et al. ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood. 2010; 116: 94-95. Abstract 0207.
  • 34
    Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408-2417.
  • 35
    Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002; 99: 1928-1937.
  • 36
    Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002; 99: 3530-3539.
  • 37
    Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009; 113: 6322-6329.
  • 38
    Sprycel (Dasatinib) [Package Insert]. Princeton, NJ: Bristol-Meyers Squibb Company; 2010.
  • 39
    Cortes J, Borthakur G, O'Brien S, et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP) [abstract]. Blood. 2009; 114: 143. Abstract 338.
  • 40
    Melnick JS, Janes J, Kim S, et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci U S A. 2006; 103: 3153-3158.
  • 41
    Abram CL, Courtneidge SA. Src family tyrosine kinases and growth factor signaling. Exp Cell Res. 2000; 254: 1-13.
  • 42
    Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol. 2009; 4: 99-105.
  • 43
    Rohon P, Porkka K, Mustjoki S. Immunoprofiling of chronic myeloid leukemia patients at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol. 2010; 85: 387-398.
  • 44
    Nagata Y, Ohashi K, Fukuda S, Kamata N, Akiyama H, Sakamaki H. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol. 2010; 91: 799-807.
  • 45
    Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009; 23: 1398-1405.
  • 46
    Palandri F, Castagnetti F, Soverini S, et al. Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. Haematologica. 2009; 94: 1758-1761.
  • 47
    Tasigna (Nilotinib) [Package Insert]. Stein, Switzerland: Novartis Pharma Stein AG; 2010.
  • 48
    Gleevec (Imatinib) [Package Insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.
  • 49
    Fitter S, Dewar AL, Kostakis P, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood. 2008; 111: 2538-2547.
  • 50
    van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001; 358: 1421-1423.
  • 51
    van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2002; 38( suppl 5): S83-S87.
  • 52
    Hochhaus A, Kantarjian H, Baccarani M, et al. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukaemia (CML) in chronic phase (CP) or accelerated phase (AP). Hematologica. 2008; 93: 56-57.
  • 53
    Guilhot F, Goldberg SL, Stone RM, et al. Dasatinib lack of cross intolerance to imatinib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) who are intolerant to imatinib—a retrospective safety analysis [abstract]. Haematologica. 2008; 93: 51. Abstract 128.
  • 54
    Cortes JE, Jones D, O'Brien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010; 28: 398-404.
  • 55
    Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003; 21: 1637-1647.
  • 56
    de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008; 141: 745-747.
  • 57
    Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007; 25: 3908-3914.
  • 58
    Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006; 12: 908-916.
  • 59
    Ribeiro AL, Marcolino MS, Bittencourt HN, et al. An evaluation of the cardiotoxicity of imatinib mesylate. Leuk Res. 2008; 32: 1809-1814.
  • 60
    Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007; 110: 1233-1237.
  • 61
    Verweij J, Casali PG, Kotasek D, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer. 2007; 43: 974-978.
  • 62
    Wolf A, Couttet P, Dong M, et al. Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leuk Res. 2010; 34: 1180-1188.
  • 63
    US Food and Drug Administration (FDA). Dasatinib (BMS-35825) Oncologic Drug Advisory Committee Briefing Document NDA 21-96. Washington, DC: FDA; 2006.
  • 64
    Quintas-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009; 114: 261-263.
  • 65
    Quintas-Cardama A, Kantarjian H, Ravandi F, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer. 2009; 115: 2482-2490.
  • 66
    Gugliotta G, Castagnetti F, Amabile M, et al. Age has no impact on outcome of early chronic phase, Ph-positive CML, imatinib treated patients: a nationwide analysis on 559 cases of the GIMEMA CML WP [abstract]. Haematologica. 2009; 94( suppl 2): 256. Abstract 0633.
  • 67
    le Coutre PD, Turkina A, Kim D-W, et al. Efficacy and safety of nilotinib in elderly patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): a sub-analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) study [abstract]. Blood. 2009; 114: 1272-1273. Abstract 3286.
  • 68
    Cavazzini F, Latagliata R, Stagno F, et al. Efficacy and safety profile of dasatinib in a subset of very elderly patients with chronic myeloid leukemia (CML) resistant/intolerant to imatinib [abstract]. Haematologica. 2010; 95: 349. Abstract 0835.
  • 69
    Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004; 104: 2655-2660.
  • 70
    Millot F, Guilhot J, Nelken B, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia. 2006; 20: 187-192.
  • 71
    Kuwabara A, Babb A, Ibrahim A, et al. Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood. 2010; 116: 1014-1016.
  • 72
    Jabbour E, Kantarjian HM, Jones D, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy Blood. 2009; 113: 2154-2160.
  • 73
    Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010; 28: 424-430.
  • 74
    Yeung DT, Osborn M, White DL, et al. Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDEL-II trial [abstract]. Blood. 2010; 116: 96. Abstract 0209.
  • 75
    Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009; 27: 4204-4210.
  • 76
    Muller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to pre-existing BCR-ABL mutations. Blood. 2009; 114: 4944-4953.